◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

Home › All stocks › AMGN

Amgen Inc (AMGN) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · Biotechnology · DATA UPDATED 2026-07-12

Amgen Inc (AMGN) operates in the Biotechnology industry and is headquartered in Thousand Oaks, United States with about 31,500 employees. Its market capitalization is roughly $203 billion. In the fiscal year ended 2025-12-31, AMGN reported $36.7B in revenue and $7.7B in net income.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.

Interactive charts & full statements → Open the AMGN valuation workbench →

AMGN Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$37.2B	$36.7B	$33.4B	$28.2B	$26.3B	$26.0B	$25.4B	$23.4B	$23.7B	$22.8B	$23.0B	$21.7B	$20.1B	$18.7B	$17.3B	$15.6B	$15.1B	$14.6B	$15.0B	$14.8B	$14.3B
Gross Profit	$26.6B	$26.0B	$20.6B	$19.7B	$19.9B	$19.5B	$19.3B	$19.0B	$19.6B	$18.8B	$18.8B	$17.4B	$15.6B	$15.3B	$14.3B	$13.2B	$12.8B	$12.6B	$12.7B	$12.2B	$12.2B
Gross Margin %	71.5%	70.8%	61.5%	70.0%	75.7%	75.2%	75.8%	81.3%	82.7%	82.2%	81.9%	80.5%	78.0%	82.1%	83.1%	84.4%	85.2%	85.7%	84.7%	82.8%	85.3%
Operating Income (EBIT)	$11.8B	$10.7B	$7.3B	$7.9B	$9.6B	$7.6B	$9.1B	$9.7B	$10.3B	$10.0B	$9.8B	$8.5B	$6.2B	$5.9B	$5.6B	$4.3B	$5.5B	$5.5B	$5.2B	$4.0B	$3.8B
Operating Margin %	31.6%	29.1%	21.7%	28.0%	36.3%	29.4%	35.9%	41.4%	43.2%	43.6%	42.6%	39.1%	30.9%	31.4%	32.3%	27.7%	36.8%	37.6%	34.8%	26.9%	26.9%
Net Income	$7.8B	$7.7B	$4.1B	$6.7B	$6.6B	$5.9B	$7.3B	$7.8B	$8.4B	$2.0B	$7.7B	$6.9B	$5.2B	$5.1B	$4.3B	$3.7B	$4.6B	$4.6B	$4.2B	$3.2B	$3.0B
Net Margin %	20.9%	21.0%	12.2%	23.8%	24.9%	22.7%	28.6%	33.6%	35.4%	8.7%	33.6%	32.0%	25.7%	27.2%	25.2%	23.6%	30.7%	31.4%	28.0%	21.4%	20.7%
EBITDA	$16.7B	$16.9B	$13.4B	$7.9B	$12.2B	$11.3B	$13.0B	$12.6B	$12.9B	$12.9B	$12.5B	$11.2B	$8.7B	$7.6B	$7.2B	$5.8B	$6.9B	$6.8B	$6.6B	$6.0B	$6.0B
Earnings Per Share (EPS)	$14.38	$14.23	$7.56	$12.49	$12.11	$10.28	$12.31	$12.88	$12.62	$2.69	$10.24	$9.06	$6.70	$6.64	$5.52	$4.04	$4.79	$4.51	$3.90	$2.82	$2.48
Shares Outstanding (M)	544M	542M	541M	538M	541M	573M	590M	609M	665M	735M	754M	766M	770M	765M	787M	912M	965M	1,021M	1,075M	1,123M	1,190M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

AMGN Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Total Revenue	$8.6B	$9.9B	$9.6B	$9.2B	$8.1B	$9.1B	$8.5B	$8.4B
Gross Profit	$5.9B	$8.1B	$6.5B	$6.2B	$5.2B	$6.0B	$5.2B	$5.2B
Gross Margin %	68.2%	81.9%	67.8%	67.2%	63.6%	65.8%	61.1%	61.4%
Operating Income (EBIT)	$2.7B	$3.9B	$2.5B	$2.6B	$1.2B	$2.3B	$2.0B	$1.9B
Operating Margin %	30.9%	39.8%	26.4%	28.8%	14.5%	25.4%	24.1%	22.8%
Net Income	$1.8B	$1.3B	$3.2B	$1.4B	$1.7B	$627M	$2.8B	$746M
Net Margin %	21.1%	13.5%	33.7%	15.6%	21.2%	6.9%	33.3%	8.9%
EBITDA	$3.9B	$3.3B	$5.9B	$3.6B	$4.1B	$2.9B	$5.3B	$3.0B
Earnings Per Share (EPS)	$3.34	$2.45	$5.93	$2.65	$3.20	$1.16	$5.22	$1.38
Shares Outstanding (M)	544M	543M	542M	541M	541M	542M	542M	541M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

AMGN Free Cash Flow History

Cash flow	TTM → 2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	$10.8B	$10.0B	$11.5B	$8.5B	$9.7B	$9.3B	$10.5B	$9.2B	$11.3B	$11.2B	$10.4B	$9.1B	$8.6B	$6.3B	$5.9B	$5.1B	$5.8B	$6.3B	$6.0B	$5.4B	$5.4B
Capital Expenditures (CapEx)	$2.2B	$1.9B	$1.1B	$1.1B	$936M	$880M	$608M	$618M	$738M	$664M	$837M	$649M	$1.0B	$693M	$689M	$567M	$580M	$530M	$672M	$1.3B	$1.2B
Free Cash Flow (FCF)	$8.6B	$8.1B	$10.4B	$7.4B	$8.8B	$8.4B	$9.9B	$8.5B	$10.6B	$10.5B	$9.5B	$8.4B	$7.6B	$5.6B	$5.2B	$4.6B	$5.2B	$5.8B	$5.3B	$4.1B	$4.2B
FCF Margin %	23.1%	22.1%	31.1%	26.1%	33.4%	32.3%	38.9%	36.5%	44.5%	46.0%	41.4%	38.9%	37.6%	30.0%	30.1%	29.2%	34.6%	39.6%	35.4%	28.0%	29.2%
Dividends Paid	$5.2B	$5.1B	$4.8B	$4.6B	$4.2B	$4.0B	$3.8B	$3.5B	$3.5B	$3.4B	$3.0B	$2.4B	$1.9B	$1.4B	$1.1B	$500M	$0M	$2.0B	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

AMGN Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Cash from Operations (CFO)	$2.2B	$1.6B	$4.7B	$2.3B	$1.4B	$4.8B	$3.6B	$2.5B
Capital Expenditures (CapEx)	$712M	$642M	$436M	$369M	$411M	$371M	$257M	$238M
Free Cash Flow (FCF)	$1.5B	$961M	$4.2B	$1.9B	$980M	$4.4B	$3.3B	$2.2B
FCF Margin %	17.1%	9.7%	44.5%	20.8%	12.0%	48.4%	39.0%	26.5%
Dividends Paid	$1.4B	$1.3B	$1.3B	$1.3B	$1.3B	$1.2B	$1.2B	$1.2B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

AMGN Balance Sheet History

Balance sheet	2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$92.5B	$90.6B	$91.8B	$97.2B	$65.1B	$61.2B	$62.9B	$59.7B	$66.4B	$80.0B	$77.6B	$71.6B	$69.0B	$66.1B	$54.3B	$48.9B	$43.5B	$39.6B	$36.4B	$34.6B	$33.8B
Cash & Cash Equivalents	$12.0B	$9.1B	$12.0B	$10.9B	$7.6B	$8.0B	$6.3B	$6.0B	$6.9B	$3.8B	$3.2B	$4.1B	$3.7B	$3.8B	$3.3B	$6.9B	$3.3B	$2.9B	$1.8B	$2.0B	$1.3B
Total Liabilities	$83.3B	$81.9B	$86.0B	$90.9B	$61.5B	$54.5B	$53.5B	$50.0B	$53.9B	$54.7B	$47.8B	$43.4B	$43.2B	$44.0B	$35.2B	$29.8B	$19.5B	$17.0B	$16.1B	$16.8B	$14.8B
Total Debt (Short + Long-Term)	$57.3B	$54.6B	$60.1B	$64.6B	$38.9B	$33.3B	$33.0B	$29.9B	$33.9B	$35.3B	$34.6B	$31.6B	$30.7B	$32.1B	$26.5B	$21.4B	$13.4B	$10.6B	$10.2B	$11.2B	$9.0B
Total Shareholders' Equity	$9.2B	$8.7B	$5.9B	$6.2B	$3.7B	$6.7B	$9.4B	$9.7B	$12.5B	$25.2B	$29.9B	$28.1B	$25.8B	$22.1B	$19.1B	$19.0B	$23.9B	$22.7B	$20.4B	$17.9B	$19.0B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive AMGN viewer.

Other Companies in Biotechnology

ABBV · AbbVie — $458 billion
GILD · Gilead Sciences — $161 billion
VRTX · Vertex Pharmaceuticals — $121 billion
REGN · Regeneron Pharmaceuticals — $69 billion
BIIB · Biogen — $30 billion
ROIV · Roivant Sciences Ltd. — $26 billion
INSM · Insmed Incorporated — $26 billion
INCY · Incyte — $24 billion

← AMG All stocks AMIX →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.